Posts

Emergency COVID-19 vaccines will have to convince a skeptical public - The Verge

Image
During the 2009 H1N1 pandemic, Sandra Quinn asked hundreds of Americans if they’d be willing to take a hypothetical vaccine that was authorized for emergency use but wasn’t formally approved by the Food and Drug Administration. Most were hesitant: Quinn, the senior associate director of the Maryland Center for Health Equity at the University of Maryland, found that only around 8 percent of people said that they’d definitely take the vaccine. An emergency H1N1 vaccine never came to be, but the questions Quinn asked 10 years ago are back in the spotlight today, as pharmaceutical companies in the US and around the world fight to produce a coronavirus vaccine as quickly as possible. It’s a real possibility that the FDA could allow for emergency use of a vaccine this time around. The United States Department of Health and Human Services (HHS) said that it aims to have doses of the AstraZeneca vaccine candidate by October — and that “emergency use authorization or licensure of this vacc...

Merck, one of Big Pharma's biggest players, reveals its COVID-19 vaccine and therapy plans - Science Magazine

Image
Announcing several partnerships today, Merck will pursue two vaccines and a therapy for COVID-19. REUTERS/Brendan McDermid By Jon Cohen May. 26, 2020 , 3:20 PM Science ’s COVID-19 reporting is supported by the Pulitzer Center. Merck, one of the largest pharmaceutical companies in the world, has been conspicuously absent from the race to develop COVID-19 vaccines and drugs. No longer. The company this morning announced it has cut deals to develop and manufacture two different COVID-19 vaccines and a much-discussed experimental antiviral compound that is already in early clinical trials. Roger Perlmutter, president of Merck Research Laboratories, portrays the company as deliberate rather than a latecomer. And the immunologist believes Merck’s skills and experience can accelerate the progress that other, smaller developers already have made. “Clearly, we have a lot of heft,” says Perlmutter, who declined to disclose how much Merck is investing in each project. Related ...

Potential cross-reactivity between MMR vaccinations and COVID-19 | TheHill - The Hill

Image
With the current COVID-19 pandemic affecting the world, not much in everyday life remains the same. Economies from the largest to the smallest have been rocked. Government lockdowns have been undertaken, the likes of which have never been experienced in the modern world. With the virus originating in Wuhan, China, several questions remain: How has the virus spread so rapidly across the globe? How long are incubation rates? ADVERTISEMENT What is the most accurate testing method? How much time is needed to develop a safe and effective vaccine? And, of course, how and when to reopen our communities? In time, many of these questions will be researched and answered, but along the way some trends have become noteworthy. For instance, the SARS-CoV-2 virus has affected some groups worse than others and this necessitates further investigation as to why. I was made aware of research being done by Dr. Larry Tilley, DVM, a world-renowned expert in veterinary medicine research, Dr. Willia...

He had a severe reaction to Moderna Covid-19 vaccine. He's still a believer - STAT

Image
P atients in clinical trials are usually faceless. But as the experimental Covid-19 vaccine being developed by Moderna Therapeutics has begun advancing through studies, it has found a much more visible advocate: trial volunteer Ian Haydon, a 29-year-old in Seattle. Haydon has spoken about the vaccine on CNN and CNBC. He even said he’d volunteer to be exposed to the novel coronavirus, SARS-CoV-2, if researchers want to test to see if the vaccine was actually effective. But up until now he has left out a key detail: He is, apparently, one of three people in the trial who had a systemic adverse reaction to the vaccine.  Twelve hours after receiving his second dose, he developed a fever of more than 103 degrees, sought medical attention, and, after being released from an urgent care facility, fainted in his home. He recovered within a day. advertisement He has not brought up the side effects previously, he said, out of “an abundance of caution.” “I understand that sharing the sto...

Montana Health Officials Fear Dual Outbreaks As Vaccinations Drop During Pandemic - MTPR

Image
Montana Health Officials Fear Dual Outbreaks As Vaccinations Drop During Pandemic The Centers for Disease Control and Prevention say the number of vaccines being given to children for diseases like polio and hepatitis B has fallen dramatically during the coronavirus pandemic. Montana’s public health departments and providers, seeing the same decline, are concerned it could lead to an outbreak of a vaccine preventable disease and pull resources away from the COVID-19 response. The CDC reports the number of childhood vaccine orders coming through a program providing free immunizations to uninsured children has seen a significant decline since states issued stay-at-home orders in mid-March. The program, called the Vaccines for Children Program, provides vaccines to about half of children under five in the U.S. While Montana has had one of the lowest COVID-19 case rates in the country, public health officials including Cindy Farr say the state is no exception. She said visits to ...

Coronavirus Vaccine Update, May 26 | In the Pipeline - Science Magazine

We have a lot more vaccine news to catch up on, and I’ll use this as a new “frontrunning vaccine candidates” post, replacing this one  (and updates therein) from about a month back. That one will give you some more general information on most of the projects below; if you haven’t read it, it’ll be a good intro. A general vaccine background post is here , and here’s a recent one one covering some other candidates. The ones below are in no particular order; no oddsmaking is implied, because you’d have to be a lunatic to try to guess which ones will work and which won’t at this point. We can be pretty sure, though, that many of them will fail for one reason or another, just because most drugs and most vaccines fail. We can also be sure that as we go along there will be likely be many hard tradeoffs to consider in efficacy, manufacturing, safety, and other issues – I’ll frankly be amazed if that doesn’t happen. So with those points out in the open, here we go – note that the J&J ...

Philly vaccine expert says coronavirus process could take years - WHYY

Image
Pennsylvania, New Jersey and Delaware are all moving to partially reopen. But health experts say only a COVID-19 vaccine can get us back to life (mostly) as we knew it, so scientists and pharmaceutical companies around the world —including some right here in the Philly area — are racing to make one ASAP. Dr. Paul Offit, who directs the Vaccine Education center at the Children’s Hospital of Philadelphia, is on a national panel overseeing vaccines being developed by American companies. He explains why vaccines take years to develop safely and why he urges companies “crowing” about their latest developments to be more humble. Interview highlights On his own experience developing a successful vaccine I was fortunate enough to be part of the team at Children’s Hospital Philadelphia that created the rotavirus vaccine — rotavirus is a cause of fever, vomiting and diarrhea. It caused about 75,000 children in the United States to be hospitalized with dehydration, meaning water loss...